{"id":2723,"date":"2023-04-27T16:19:25","date_gmt":"2023-04-27T20:19:25","guid":{"rendered":"https:\/\/amrefcanada.org\/?p=2723"},"modified":"2023-04-27T16:19:25","modified_gmt":"2023-04-27T20:19:25","slug":"gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines","status":"publish","type":"post","link":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/","title":{"rendered":"Gavi outlines plans to build a sustainable supply of malaria vaccines"},"content":{"rendered":"<ul>\n<li>Following successful pilots, 2023 will see countries start to prepare for the rollout of the world\u2019s first malaria mass vaccinations; however, long-term supply and affordability remain a challenge.<\/li>\n<li>A new paper published today by Gavi outlines how the world can increase supply to meet demand within the next few years by growing the number of manufacturers and supporting scale-up through predictable demand.<\/li>\n<li>Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance: \u201cIt has taken the world more than 50 years to develop a malaria vaccine. Yet this year\u2019s launch serves only as a reminder of what needs to happen now if we are to make malaria vaccines accessible to every child that needs them.\u201d<\/li>\n<\/ul>\n<p><strong>Geneva, 25 April 2023 \u2013\u00a0<\/strong>The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a\u00a0<a href=\"https:\/\/www.gavi.org\/news\/document-library\/malaria-vaccine-market-shaping-roadmap\">white paper<\/a>\u00a0outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.<\/p>\n<p>With 475,000 deaths of children under the age of 5 in 2021 on the African continent alone, malaria remains one of Africa\u2019s biggest killers, despite concerted efforts that have seen the global death toll drop by a third since 2000. The pre-qualification of the world\u2019s first malaria vaccine \u2013 RTS,S\/AS01e, developed and manufactured by GSK and which took more than three decades to develop \u2013 will save more lives, while a second vaccine, R21\/Matrix-M, developed by Oxford University and manufactured by Serum Institute of India (SII), could also be prequalified and recommended by WHO very soon.<\/p>\n<p>The major impediment that now stands in the way of a widespread rollout of malaria vaccines in endemic countries is supply. According to\u00a0<a href=\"https:\/\/www.gavi.org\/news\/document-library\/malaria-vaccine-market-shaping-roadmap\">Gavi\u2019s market shaping roadmap for malaria vaccines<\/a>, a production target of 40-60 million doses by 2026 is needed to meet countries\u2019 needs, increasing to 80-100 million doses by 2030. Such an outcome would require countries and partners to work together in key areas such as demand forecasting, boosting the number of suppliers and technology transfer, the report argues. The report also outlines Gavi\u2019s commitment to additional co-financing to ensure countries can access doses, support for countries to make timely applications, and foster further innovation in malaria vaccination and greater integration with existing interventions.<\/p>\n<p>\u201cIt has taken the world more than 50 years to develop a malaria vaccine,\u201d said Dr Seth Berkley, CEO of Gavi. \u201cYet this year\u2019s launch serves only as a reminder of what needs to happen now if we are to make malaria vaccines accessible to every child that needs them. We know how long African countries have waited for a vaccine against one of its greatest killers: if global health, countries, suppliers and civil society come together, we can soon contribute to preventing tens of thousands of child deaths every year along with other malaria control interventions.\u201d<\/p>\n<p>Gavi\u2019s market shaping work over more than 22 years has helped bring down prices and increase the supply of life-saving vaccines and made them available to children everywhere with a focus on reaching zero dose children. With concerted efforts, Gavi and its partners will do the same for malaria.<\/p>\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<p><strong>Notes to editors<\/strong><\/p>\n<p><strong>About Gavi, the Vaccine Alliance<\/strong><\/p>\n<p>Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world\u2019s children against some of the world\u2019s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation \u2013 over 981 million children \u2013 and prevented more than 16.2 million future deaths, helping to halve child mortality in 73 lower-income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation, above all the zero-dose children who have not received even a single vaccine shot. The Vaccine Alliance employs innovative finance and the latest technology \u2013 from drones to biometrics \u2013 to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at\u202f<a href=\"https:\/\/www.gavi.org\/homepage\" target=\"_blank\" rel=\"noreferrer noopener\">www.gavi.org<\/a>\u202fand connect with us on\u202f<a href=\"https:\/\/www.facebook.com\/GAVI\/\" target=\"_blank\" rel=\"noreferrer noopener\">Facebook<\/a>\u202fand\u202f<a href=\"https:\/\/twitter.com\/gavi\" target=\"_blank\" rel=\"noreferrer noopener\">Twitter<\/a>.<\/p>\n<p>Gavi is a co-convener of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, together with the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization (WHO) and UNICEF. In its role, Gavi is focused on procurement and delivery for COVAX: coordinating the design, implementation and administration of the COVAX Facility and the Gavi COVAX AMC and working with its Alliance partners UNICEF and WHO, along with governments, on country readiness and delivery.<\/p>\n<p>The Vaccine Alliance brings together developing countries and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill &amp; Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organisations that fund Gavi\u2019s work\u202f<a href=\"https:\/\/www.gavi.org\/investing-gavi\/funding\/donor-profiles\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n<p>Article first published on\u00a0<a href=\"https:\/\/www.gavi.org\/news\/media-room\/gavi-outlines-plans-build-sustainable-supply-malaria-vaccines\">https:\/\/www.gavi.org\/news\/media-room\/gavi-outlines-plans-build-sustainable-supply-malaria-vaccines<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following successful pilots, 2023 will see countries start to prepare [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":2724,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[85,86],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gavi outlines plans to build a sustainable supply of malaria vaccines &#8212; Amref Canada<\/title>\n<meta name=\"description\" content=\"Geneva, 25 April 2023 \u2013 The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gavi outlines plans to build a sustainable supply of malaria vaccines &#8212; Amref Canada\" \/>\n<meta property=\"og:description\" content=\"Geneva, 25 April 2023 \u2013 The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\" \/>\n<meta property=\"og:site_name\" content=\"Amref Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/amrefcanada\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T20:19:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wanjiru-Munene\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@amrefcanada\" \/>\n<meta name=\"twitter:site\" content=\"@amrefcanada\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wanjiru-Munene\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\"},\"author\":{\"name\":\"Wanjiru-Munene\",\"@id\":\"https:\/\/amrefcanada.org\/#\/schema\/person\/9cf91ea7a27cd896d201bd0df59935d5\"},\"headline\":\"Gavi outlines plans to build a sustainable supply of malaria vaccines\",\"datePublished\":\"2023-04-27T20:19:25+00:00\",\"dateModified\":\"2023-04-27T20:19:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\"},\"wordCount\":859,\"publisher\":{\"@id\":\"https:\/\/amrefcanada.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg\",\"keywords\":[\"Malaria\",\"Malaria vaccine\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\",\"url\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\",\"name\":\"Gavi outlines plans to build a sustainable supply of malaria vaccines &#8212; Amref Canada\",\"isPartOf\":{\"@id\":\"https:\/\/amrefcanada.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg\",\"datePublished\":\"2023-04-27T20:19:25+00:00\",\"dateModified\":\"2023-04-27T20:19:25+00:00\",\"description\":\"Geneva, 25 April 2023 \u2013 The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.\",\"breadcrumb\":{\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage\",\"url\":\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg\",\"contentUrl\":\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg\",\"width\":1080,\"height\":720,\"caption\":\"EPI Nurse Janet Mula retrieves vials with the malaria vaccine from a refrigerator at the Malava County Hospital, Kakamega, Kenya. Credit: Gavi\/2021\/White Rhino Films-Lameck Orina\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/amrefcanada.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gavi outlines plans to build a sustainable supply of malaria vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/amrefcanada.org\/#website\",\"url\":\"https:\/\/amrefcanada.org\/\",\"name\":\"Amref Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/amrefcanada.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/amrefcanada.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/amrefcanada.org\/#organization\",\"name\":\"Amref Health Africa Canada\",\"url\":\"https:\/\/amrefcanada.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/amrefcanada.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2021\/01\/logo-1.png\",\"contentUrl\":\"https:\/\/amrefcanada.org\/wp-content\/uploads\/2021\/01\/logo-1.png\",\"width\":300,\"height\":178,\"caption\":\"Amref Health Africa Canada\"},\"image\":{\"@id\":\"https:\/\/amrefcanada.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/amrefcanada\",\"https:\/\/twitter.com\/amrefcanada\",\"https:\/\/www.instagram.com\/amrefcanada\/\",\"https:\/\/www.linkedin.com\/company\/674833\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/amrefcanada.org\/#\/schema\/person\/9cf91ea7a27cd896d201bd0df59935d5\",\"name\":\"Wanjiru-Munene\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/amrefcanada.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/819e5ceeeea2037e98cb35916049f195?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/819e5ceeeea2037e98cb35916049f195?s=96&d=mm&r=g\",\"caption\":\"Wanjiru-Munene\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gavi outlines plans to build a sustainable supply of malaria vaccines &#8212; Amref Canada","description":"Geneva, 25 April 2023 \u2013 The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/","og_locale":"en_US","og_type":"article","og_title":"Gavi outlines plans to build a sustainable supply of malaria vaccines &#8212; Amref Canada","og_description":"Geneva, 25 April 2023 \u2013 The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.","og_url":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/","og_site_name":"Amref Canada","article_publisher":"https:\/\/www.facebook.com\/amrefcanada","article_published_time":"2023-04-27T20:19:25+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg","type":"image\/jpeg"}],"author":"Wanjiru-Munene","twitter_card":"summary_large_image","twitter_creator":"@amrefcanada","twitter_site":"@amrefcanada","twitter_misc":{"Written by":"Wanjiru-Munene","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#article","isPartOf":{"@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/"},"author":{"name":"Wanjiru-Munene","@id":"https:\/\/amrefcanada.org\/#\/schema\/person\/9cf91ea7a27cd896d201bd0df59935d5"},"headline":"Gavi outlines plans to build a sustainable supply of malaria vaccines","datePublished":"2023-04-27T20:19:25+00:00","dateModified":"2023-04-27T20:19:25+00:00","mainEntityOfPage":{"@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/"},"wordCount":859,"publisher":{"@id":"https:\/\/amrefcanada.org\/#organization"},"image":{"@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg","keywords":["Malaria","Malaria vaccine"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/","url":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/","name":"Gavi outlines plans to build a sustainable supply of malaria vaccines &#8212; Amref Canada","isPartOf":{"@id":"https:\/\/amrefcanada.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg","datePublished":"2023-04-27T20:19:25+00:00","dateModified":"2023-04-27T20:19:25+00:00","description":"Geneva, 25 April 2023 \u2013 The world\u2019s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal.","breadcrumb":{"@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#primaryimage","url":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg","contentUrl":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2023\/04\/RS39354_GAVI-Malaria-Vaccine-KE-184_h2.jpg","width":1080,"height":720,"caption":"EPI Nurse Janet Mula retrieves vials with the malaria vaccine from a refrigerator at the Malava County Hospital, Kakamega, Kenya. Credit: Gavi\/2021\/White Rhino Films-Lameck Orina"},{"@type":"BreadcrumbList","@id":"https:\/\/amrefcanada.org\/news\/gavi-outlines-plans-to-build-a-sustainable-supply-of-malaria-vaccines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/amrefcanada.org\/"},{"@type":"ListItem","position":2,"name":"Gavi outlines plans to build a sustainable supply of malaria vaccines"}]},{"@type":"WebSite","@id":"https:\/\/amrefcanada.org\/#website","url":"https:\/\/amrefcanada.org\/","name":"Amref Canada","description":"","publisher":{"@id":"https:\/\/amrefcanada.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/amrefcanada.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/amrefcanada.org\/#organization","name":"Amref Health Africa Canada","url":"https:\/\/amrefcanada.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/amrefcanada.org\/#\/schema\/logo\/image\/","url":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2021\/01\/logo-1.png","contentUrl":"https:\/\/amrefcanada.org\/wp-content\/uploads\/2021\/01\/logo-1.png","width":300,"height":178,"caption":"Amref Health Africa Canada"},"image":{"@id":"https:\/\/amrefcanada.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/amrefcanada","https:\/\/twitter.com\/amrefcanada","https:\/\/www.instagram.com\/amrefcanada\/","https:\/\/www.linkedin.com\/company\/674833\/admin\/"]},{"@type":"Person","@id":"https:\/\/amrefcanada.org\/#\/schema\/person\/9cf91ea7a27cd896d201bd0df59935d5","name":"Wanjiru-Munene","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/amrefcanada.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/819e5ceeeea2037e98cb35916049f195?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/819e5ceeeea2037e98cb35916049f195?s=96&d=mm&r=g","caption":"Wanjiru-Munene"}}]}},"_links":{"self":[{"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/posts\/2723"}],"collection":[{"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/comments?post=2723"}],"version-history":[{"count":3,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/posts\/2723\/revisions"}],"predecessor-version":[{"id":2727,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/posts\/2723\/revisions\/2727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/media\/2724"}],"wp:attachment":[{"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/media?parent=2723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/categories?post=2723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amrefcanada.org\/wp-json\/wp\/v2\/tags?post=2723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}